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The retrograde approach is essential for contempo-rary chronic total occlusion (CTO) percutaneous coronary intervention (PCI) and involves advance-
ment of a guidewire through a collateral vessel or a bypass 
graft distal to the occlusion, followed by crossing against 
the former direction of blood flow.1-5 Septal collaterals are 
the most commonly used vessels for retrograde CTO-PCI, 
whereas epicardial collaterals are used less commonly, as 
they can be more challenging to cross and carry higher 
risk for tamponade in case of perforation.6 Saphenous vein 
grafts (both patent and occluded) are also commonly used 
for retrograde CTO-PCI,7,8 although they carry risk for 
perforation and other complications as well.9-13 Left inter-
nal mammary artery (LIMA) grafts are the least preferred 
retrograde channels due to the large area of myocardium 
they supply with the concomitant risk for severe isch-
emia.14-18 Moreover, LIMA grafts are often highly tortuous, 
and straightening with guidewires and/or microcatheters 
may result in pseudolesions and compromised flow.19 We 
examined a contemporary multicenter registry to deter-
mine the frequency and outcomes of retrograde CTO-PCI 
via LIMA grafts.
Methods
We analyzed the clinical, angiographic, and procedur-
al characteristics of retrograde CTO-PCI via LIMA grafts 
among 990 retrograde cases in 976 patients included in the 
PROGRESS CTO (Prospective Global Registry for the 
Study of Chronic Total Occlusion Intervention) registry 
(NCT02061436) between January 2012 and April 2017 at 
18 United States centers. Some centers only enrolled pa-
tients during part of the study period due to participation 
in other studies. The study was approved by the Institutional 
Review Board of each center. 
Definitions. Coronary CTOs were defined as coronary 
lesions with Thrombolysis in Myocardial Infarction (TIMI) 
grade 0 flow of at least 3-month duration. Estimation of the 
duration of occlusion was clinical, based on the first onset 
of angina, prior history of myocardial infarction in the tar-
get-vessel territory, or comparison with a prior angiogram. 
Calcification was assessed by angiography as mild (spots), mod-
erate (involving ≤50% of the reference lesion diameter), or 
severe (involving >50% of the reference lesion diameter). 
Moderate proximal vessel tortuosity was defined as the presence 
of at least 2 bends >70° or 1 bend >90°, while severe tortuosity 
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also similar between the LIMA and non-LIMA retrograde groups (5% vs 6%; P>.99). Use of guide-catheter extensions (40% vs 28%; 
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in retrograde CTO-PCIs via LIMA grafts. Conclusions. Retrograde CTO-PCI is infrequently performed via LIMA grafts and is associated 
with similar success and major in-hospital complication rates as retrograde CTO-PCI performed via other conduits.
J INVASIVE CARDIOL 2018;30(3):89-96. Epub 2017 November 15.


















TAJTI, eT Al. ReTRogRAde CTo-PCI vIA lIMA gRAfTs
90 The JourNal of INVasIVe cardIology®
was defined as 2 bends >90° or 1 bend >120° in the CTO 
vessel. Blunt or no stump was defined as lack of tapering or lack 
of a funnel shape at the proximal cap. Interventional collaterals 
were defined as collaterals considered amenable to crossing 
by a guidewire and a microcatheter by the operator. A pro-
cedure was defined “retrograde” if an attempt was made to 
cross the lesion through a collateral vessel or bypass graft 
supplying the target vessel distal to the lesion. Retrograde PCI 
via LIMA was defined as interventions that used the LIMA 
as retrograde pathway, while retrograde PCI via non-LIMA de-
scribed any retrograde interventions through other collateral 
vessels or saphenous vein grafts. Antegrade dissection/re-entry 
was defined as antegrade PCI during which a guidewire was 
intentionally introduced into the subintimal space proxi-
mal to the lesion, or re-entry into the distal true lumen was 
attempted following intentional or inadvertent subintimal 
guidewire crossing.
Technical success was defined as 
successful CTO revascularization 
with achievement of <30% resid-
ual diameter stenosis within the 
treated segment and restoration 
of TIMI grade 3 antegrade flow. 
Procedural success was defined as the 
achievement of technical success 
without any in-hospital compli-
cations. In-hospital major adverse 
cardiac events (MACE) included any 
of the following adverse events 
prior to hospital discharge: death, 
myocardial infarction, recurrent 
symptoms requiring urgent repeat 
target-vessel revascularization with 
PCI or coronary artery bypass 
graft (CABG) surgery, tamponade 
requiring either pericardiocentesis 
or surgery, and stroke. Myocardial in-
farction was defined using the Third 
Universal Definition of Myocar-
dial Infarction (type 4 myocardial 
infarction).20 Major bleeding was de-
fined as bleeding causing reduction 
in hemoglobin >3 g/dL or bleed-
ing requiring transfusion or surgi-
cal intervention. The J-CTO score 
was calculated as described by Mo-
rino et al,21 the PROGRESS-CTO 
score as described by Christopoulos 
et al,22 and the PROGRESS-CTO 
complications score as described by 
Danek et al.23
Statistical analysis. Categor-
ical variables were expressed as 
percentages and were compared 
using Pearson’s Chi-square test or Fisher’s exact test. Contin-
uous variables were presented as mean ± standard deviation 
or median with interquartile range (IQR) unless otherwise 
specified, and were compared using the t-test or Wilcoxon 
rank-sum test, as appropriate. All statistical analyses were per-
formed with JMP 13.0 (SAS Institute). A two-sided P-value 
of .05 was considered statistically significant.
Results
Clinical and angiographic characteristics. The retro-
grade approach was used in 990 of 2465 cases (40.16%) per-
formed during the study period and the LIMA graft was used 
as retrograde channel in 20 cases (2.02% of all retrograde cas-
es). The baseline clinical and angiographic features are sum-
marized in Table 1 and Table 2. Mean age was higher in the 
LIMA group (69 ± 7 years vs 65 ± 10 years; P=.05) and most 
patients were men in both groups (94.7% vs 85.0%; P=.50). 
Table 1. Clinical characteristics, classified according to whether a LIMA graft was used as 
retrograde channel during chronic total occlusion percutaneous coronary intervention.
Clinical Characteristics Overall 
(n = 976)
Retrograde 







Age (years) 65.49 ± 10.06 69.13 ± 6.92 65.41 ± 10.11 .05
Male gender 87.05% 94.74% 84.97% .50
Body mass index (kg/m2) 30.68 ± 6.06 28.23 ± 4.22 30.75  ± 6.09 .03
Smoking (current) 25.00% 20.00% 25.12% .80
Diabetes 44.00% 45.00% 43.97% >.99
Dyslipidemia 95.95% 100.00% 95.86% >.99
Hypertension 90.37% 95.00% 90.26% .71
CAD presentation .55
   STEMI 1.18% 0.00% 1.21%
   NSTEMI 4.86% 5.26% 4.85%
   Unstable angina 22.34% 36.84% 21.97%
   Stable angina 62.16% 57.89% 62.26%
   No symptoms, no angina 6.83% 0.00% 7.01%
   Unlikely to be ischemic 2.63% 0.00% 2.70%
Prior MI 49.17% 50.00% 49.15% >.99
Congestive heart failure 31.89% 40.00% 31.69% .47
Prior valve procedure 3.73% 10.00% 3.58% .17
Prior PCI 72.13% 78.95% 71.99% .61
Prior CVD 11.81% 20.00% 11.61% .28
Prior PVD 17.83% 15.79% 17.88% >.99
Chronic lung disease 16.38% 20.00% 16.29% .55







Left ventricular EF (%) 49.07 ± 13.52 48.31 ± 15.38 49.08 ± 13.48 .85
Data presented as percentage, median (interquartile range), or mean ± standard deviation.
CAD = coronary artery disease; STEMI = ST-elevation myocardial infarction; NSTEMI = non-ST elevation myo-
cardial infarction; MI = myocardial infarction; PCI = percutaneous coronary intervention; CVD = cerebrovascu-
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The CTO target vessel in 
the LIMA group was the right 
coronary artery (55%), left cir-
cumflex (15%), left main (10%), 
and left anterior descending 
artery (20%). Median occlusion 
length was 40 mm (IQR, 30-
60 mm) and median target ves-
sel diameter was 3 mm (IQR, 
2.5-3.75 mm). Patients under-
going retrograde CTO-PCI 
via LIMA grafts vs non-LIMA 
conduits were likely to have 
proximal cap ambiguity (63.2% 
vs 50.4%; P=.35) and blunt or 
no stump at the proximal cap 
(84.2% vs 70.9%; P=.30). The 
mean J-CTO scores (3.45 ± 
0.76 vs 3.15 ± 1.05; P=.10), 
PROGRESS CTO scores 
(2.00 ± 0.84 vs 1.86 ± 0.91; 
P=.52), and PROGRESS 
CTO complications scores 
(4.73 ± 1.44 vs 4.25 ± 1.68; 
P=.22) were similar. 
Interventional techniques. 
The CTO crossing techniques 
used in patients in whom retro-
grade crossing via LIMA grafts 
was attempted are shown in 
Table 2. Angiographic characteristics, classified according to whether a LIMA graft was used 
as a retrograde channel during chronic total occlusion percutaneous coronary intervention.
Angiographic Characteristics Overall 
(n = 990)
Retrograde 
PCI via LIMA 
(n = 20)
Retrograde PCI 





   Right coronary 68.93% 55.00% 69.23%
   Left circumflex 16.54% 15.00% 16.58%
   Left main 0.42% 10.00% 0.22%
   Left anterior descending 14.10% 20.00% 13.98%
CTO length (mm) 39.5 (25-60) 40 (30-60) 39 (25-60) .68
Vessel diameter (mm) 3 (2.5-3) 3 (2.5-3.75) 3 (2.5-3) .45
Proximal cap ambiguity 50.72% 63.16% 50.37% .35
Side branch at proximal cap 54.39% 63.16% 54.14% .49
Blunt stump/no stump 71.24% 84.21% 70.88% .30
Distal cap at bifurcation 47.38% 36.84% 47.68% .48
Moderate/severe calcification 70.06% 70.00% 70.07% >.99
Moderate/severe tortuosity 46.65% 47.37% 46.63% >.99
Prior failed CTO-PCI 24.79% 15.79% 24.97% .43
Interventional collaterals 77.01% 78.95% 76.96% >.99
In-stent restenosis 14.79% 16.67% 14.75% .74
J-CTO score 3.15 ± 1.04 3.45 ± 0.76 3.15 ± 1.05 .10
PROGRESS CTO score 1.87 ± 0.91 2.00 ± 0.84 1.86 ± 0.91 .51
PROGRESS CTO complications score 4.26 ± 1.67 4.73 ± 1.44 4.25 ± 1.68 .22
Data presented as percentage, median (interquartile range), or mean ± standard deviation.
LIMA = left internal mammary artery; CTO = chronic total occlusion; PCI = percutaneous coronary inter-
vention; J = Japan; PROGRESS = Prospective Global Registry of Chronic Total Occlusion Interventions.
FIGURE 1. Application of hybrid approach during retrograde chronic total occlusion percutaneous coronary intervention via left inter-
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Figure 1, and the overall technical characteristics are listed in 
Table 3. An initial antegrade crossing attempt was used in 12 
patients (60%) and a primary retrograde approach was used 
in the remaining 8 cases (40%). The success rate of the ini-
tially applied crossing technique was low (only 2 cases in the 
primary retrograde group). After failure of antegrade-wire es-
calation, retrograde crossing was attempted in all cases except 
1 case in which antegrade dissection/re-entry was used. In 5 
cases, three or more crossing strategies were used, with success 
in 4 cases. 
Overall, antegrade-wire escalation was attempted in 14 
cases (70%), but was only successful in 1 case, after multi-
ple failed retrograde or antegrade dissection re-entry crossing 
attempts. Antegrade dissection re-entry was used in 5 cases 
(25%) – in most cases after a failed retrograde crossing attempt 
– and was successful in 2 cases (10%) using Stingray-based 
re-entry (Boston Scientific) in 1 case and wire-based re-entry 
in the other. Retrograde crossing through a LIMA graft was at-
tempted in every case and the CTO was successfully crossed in 
12 patients (60%). In 11 cases, the lesion crossings were carried 
out via the LIMA graft, while 1 of them was crossed through 
a saphenous vein graft and an epicardial collateral. Among the 
successful retrograde cases, the following crossing techniques 
were applied: reverse controlled antegrade and retrograde 
tracking (CART) in 6 cases, GuideLiner reverse CART in 
1 case (Figure 2), and true retrograde lumen puncture in 5 
cases. Intravascular ultrasound tended to be used more com-
monly in the LIMA group (45.0% vs 31.4%; P=.20), as were 
guide-catheter extensions (40.0% vs 27.9%; P=.22). 
Bifemoral approach was used in 9 cases (45%) and biradial 
approach was used in 2 cases. Use of left radial access was sig-
nificantly higher in the LIMA group (55.0% vs 22.2%; P=.02). 
FIGURE 2. Left-main chronic total occlusion (CTO) percutaneous coronary intervention (PCI) using a left internal mammary artery 
(LIMA) graft as a retrograde channel, with prophylactic use of veno-arterial extracorporeal membrane oxygenator (VA-ECMO). (A) 
Dual injection demonstrating flush occlusion of the left main coronary artery (arrowheads). (B) LIMA graft supplying the mid left ante-
rior descending  (LAD) coronary artery, which was occluded proximal and distal to the anastomosis. (C) Failed antegrade attempt for 
CTO crossing (arrowheads). (D) Retrograde wiring through the LIMA in the proximal LAD and the left main, using a SuperCross 
microcatheter and a Pilot 200 guidewire. (E) GuideLiner reverse controlled antegrade and retrograde tracking (CART) technique for 
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In 6 cases, triple arterial access was used, including the left radial 
approach in 5 cases (in 1 patient, brachial access was attempted 
for providing appropriate IMA guide-catheter support). 
Procedural outcomes and complications. The pro-
cedural outcomes are shown in Table 4. Technical and pro-
cedural success in the retrograde via LIMA grafts was 70% 
and 70%, respectively, and was similar with other retrograde 
cases (81% and 78%; P=.25 and P=.41, respectively). Median 
contrast volumes (300 mL [IQR, 250-346 mL] vs 300 mL 
[IQR, 222.5-420 mL]; P=.70), patient air-kerma doses (3.54 
Gy [IQR, 2.91-5.23 Gy] vs 3.85 Gy [IQR, 1.50-5.78 Gy]; 
P=.92), and fluoroscopy times (89.4 min [IQR, 61-126 min] 
vs 76.9 min [IQR, 54.9-103 min]; P=.14) were also similar 
in the two study groups, whereas procedural time (222.5 
min [IQR, 174-311.5 min] vs 189 min [IQR, 134-245 min]; 
P=.03) was longer in the LIMA group.
Use of mechanical circulatory support was numerically 
higher in the LIMA vs non-LIMA group (23.5% vs 9.5%; 
P=.08). Mechanical circulatory support 
was used in 4 retrograde via LIMA cas-
es (prophylactic in 3 and elective in 1); 
both Impella (Abiomed) and veno-ar-
terial extracorporeal membrane oxy-
genator (VA-ECMO) were used. One 
patient initially had an Impella device 
that was changed to VA-ECMO due to 
progressive cardiogenic shock. 
The incidence of in-hospital 
MACE was similar in the LIMA and 
control retrograde groups (5.0% vs 
5.5%; P>.99). One patient in the 
LIMA group had a complication; the 
CTO was successfully crossed using 
the reverse-CART technique. The 
CTO was balloon uncrossable, requir-
ing laser atherectomy that led to cor-
onary perforation of the target vessel 
(left main), which necessitated place-
ment of a covered stent that jailed the 
circumflex and led to periprocedural 
myocardial infarction.
Other complications were common 
in both the LIMA and non-LIMA 
retrograde groups (25.0% vs 16.7%; 
P=.36). Five complications occurred 
in the LIMA group. LIMA dissection 
occurred in 1 patient, but did not 
compromise flow and no additional 
treatment was required. Three patients 
had a vascular access complication (1 
patient who was supported by ECMO 
required surgical correction of a pseu-
doaneurysm and 2 patients developed 
groin hematoma without need for 
surgical correction). One patient developed acute kidney 
failure requiring hemodialysis. 
Procedural outcomes among patients with prior 
CABG. The procedural outcomes of patients with prior 
CABG who underwent retrograde CTO intervention are 
listed in Table 5. Prior CABG was common among retro-
grade CTO-PCI (46.0%) and the overall technical and pro-
cedural success rates were 79.4% and 77.6%, respectively, 
which was comparable with the retrograde LIMA group 
(P=.27). The overall procedural complications were high in 
CABG patients (19.7%), as they were in retrograde PCIs 
via LIMA (25.0% vs 19.4%; P=.56), and in-hospital major 
complications remained similarly low (5.0% vs 5.1%; P>.99). 
Discussion
To the best of our knowledge, this is the first systemat-
ic study of retrograde CTO-PCI via LIMA grafts. LIMA 
grafts were infrequently used for retrograde CTO-PCI, but 
Table 3. Technical characteristics, classified according to whether a LIMA graft was 
used as retrograde channel during chronic total occlusion percutaneous coronary 
intervention.
Technical Characteristics Overall 
(n = 990)
Retrograde 








Dual injection 86.22% 85.00% 86.26% .75
Right femoral access 86.46% 85.00% 86.49% .74
Left femoral access 72.22% 60.00% 72.47% .22
Right radial access 27.47% 25.00% 27.53% >.99
Left radial access 22.83% 55.00% 22.16% <.01
Right brachial access 0.20% 0.00% 0.21% >.99
Left brachial access 0.10% 5.00% 0.00% .20
Crossing strategies used
   Antegrade wire escalation 61.31% 70.00% 61.13% .49
   Antegrade dissection/re-entry 38.69% 25.00% 38.97% .25
   Retrograde 100% 100% 100% —
First crossing strategy .35
   Antegrade wire escalation 48.88% 60.00% 48.65%
   Antegrade dissection/re-entry 7.42% 0.00% 7.57%
   Retrograde 43.70% 40.00% 43.78%
Final crossing strategy .75
   Antegrade wire escalation 7.42% 5.00% 7.46%
   Antegrade dissection/re-entry 15.14% 10.00% 15.23%
   Retrograde 60.04% 60.00% 59.98%
   None 17.40% 25.00% 17.39%
Guide-catheter extensions 27.88% 40.00% 27.63% .22
Intravascular ultrasound use 31.72% 45.00% 31.44% .20
Stents used (n) 2.88 ± 1.17 3.39 ± 1.61 2.88 ± 1.16 .28
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were associated with similar technical and procedural success 
rates. Use of LIMA grafts was associated with higher risk for 
vascular access complications and a trend for more frequent 
use of mechanical circulatory support devices. 
The retrograde approach is critical to the success of CTO 
PCI, as demonstrated in several studies from around the 
world.3,24,25 However, it carries higher risk for complications 
as compared with antegrade-only crossing strategies, espe-
cially in older patients, longer lesions,23 and prior CABG 
patients.26,27 The availability of “interventional” collaterals, ie, 
collaterals that appear amenable to retrograde crossing with 
guidewires and microcatheters, is necessary to perform ret-
rograde CTO-PCI. Several patterns of septal and epicardial 
collaterals were recently described,28 along with a collateral 
scoring system for predicting their crossability. Septal collat-
erals are preferred over epicardial collaterals for retrograde 
CTO-PCI, as they carry low risk for complications.29,30 Sa-
phenous vein grafts are also appealing for retrograde CTO-
PCI, even when they are occluded.7,8 LIMA grafts are rarely 
used for retrograde CTO-PCI, be-
cause they carry higher intrinsic risk 
for complications for several reasons. 
First, LIMA grafts are often tortuous 
and advancing guidewires and micro-
catheters may result in straightening 
of the graft and an “accordion” effect, 
leading to compromised flow and 
ischemia. Second, dissection of the 
LIMA graft origin can occur; hence, 
large guide catheters (such as 7 Fr or 8 
Fr) are not usually used in these cases. 
Third, LIMA grafts are usually anasto-
mosed to the left anterior descending 
artery, and compromising their flow 
can lead to severe ischemia. Fourth, 
LIMA grafts have excellent long-term 
patency, so attempts to prevent vessel 
injury are critical.
Given the potentially catastrophic 
risks associated with their use, LIMA 
grafts should only be used for retro-
grade CTO-PCI when no other op-
tions exist and the potential benefits 
of the procedure are substantial. Our 
study demonstrates that LIMA grafts 
can be successfully used in such cas-
es with good success and acceptable 
complication rates. Donor-vessel dis-
section occurred in just 1 case; there 
was no flow limitation, and the pro-
cedure was carried out uneventfully 
without any additional treatment of 
the LIMA. To prevent LIMA graft in-
jury, guide catheters should be select-
ed carefully, with softer tips and small diameters (usually 6 
Fr or smaller) to avoid pressure dampening. Guide-catheter 
extensions should be used infrequently, as they may predis-
pose to LIMA dissection.31 Given the potential for severe 
ischemia with retrograde CTO-PCI via LIMA grafts, such 
procedures may more often need to be performed using 
hemodynamic support devices, which at least in part ex-
plains the higher rate of vascular access complications. An 
alternative to using LIMA grafts and septal collaterals for 
retrograde PCI or right coronary artery CTOs is to per-
form left main and/or left anterior descending CTO inter-
vention as a first step, followed by retrograde CTO-PCI via 
septal collaterals.
Study limitations. Our study has several limitations. 
The number of patients included was relatively small and 
we did not have long-term follow-up. The power of the 
study is low given the small number of cases with PCI via 
the LIMA graft, and further evaluation is needed with large 
patient cohorts. There was no core laboratory assessment 
Table 4. Procedural outcomes among patients undergoing retrograde chronic total 
occlusion percutaneous coronary intervention (CTO-PCI), classified according to 
whether a LIMA graft was used as retrograde channel during CTO-PCI.
Procedural Outcomes Overall 
(n = 976)
Retrograde 








Technical success 80.81% 70.00% 81.03% .25
Procedural success 78.00% 70.00% 78.19% .41
Procedural complications 16.93% 25.00% 16.74% .36




























In-hospital MACE 5.53% 5.00% 5.54% >.99
Death 1.43% 0.00% 1.46% >.99
Acute MI 2.25% 5.00% 2.20% .37
Stroke 0.31% 0.00% 0.31% >.99
Re-PCI 0.72% 0.00% 0.73% >.99
Re-CABG 0.10% 0.00% 0.10% >.99
Pericardial tamponade 1.64% 0.00% 1.67% >.99
Vascular access complication 1.84% 15.00% 1.57% <.01
Acute kidney injury 0.41% 5.00% 0.31% .08
Donor vessel dissection/
thrombosis
2.22% 5.00% 2.16% .36
LVAD use 9.87% 23.53% 9.52% .08
Data presented as percentage or median (interquartile range).
MACE = major adverse cardiovascular events; MI = myocardial infarction; PCI = percutaneous 
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of the study angiograms or clinical 
events committee adjudication. The 
procedures were performed by ex-
perienced CTO operators in dedi-
cated, high-volume centers, limiting 
extrapolation to less experienced 
operators and centers. 
Conclusion
LIMA grafts are infrequent-
ly used for retrograde CTO-PCI; 
however, their use is associated with 
similar technical and procedural 
success when compared with other 
retrograde procedures. In the hands 
of experienced operators and when 
performed with great caution, retro-
grade CTO-PCI via LIMA graft can 
be a valuable tool for highly com-
plex CTO-PCI cases. 
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for tracking data manipulation and export procedures; (3) 
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to common statistical packages; and (4) procedures for im-
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